On September 28, 2021, Amsterdam-based blockchain startup Triall officially launched its main utility token TRL via an Initial DEX Offering (IDO) on Uniswap, following a successful token pre-sale that raised over $2 million. The company introduces a tokenized ecosystem designed to secure and streamline the development of new vaccines and therapeutics during clinical trials. As part of the launch, Triall also announced a staking program powered by DeFi company Ferrum Network, offering early adopters annual percentage rates (APRs) of up to 250%.
Addressing Long-Standing Inefficiencies in Clinical Trials
Modern clinical trials are increasingly complex, lengthy, and resource-intensive. On average, it takes 10 years for a new medicine to reach the market after clinical trials. The exceptionally fast development of COVID-19 vaccines last year demonstrated that when stakeholders and efforts align, there are clear opportunities to improve the speed and rigor of clinical trial operations. Triall is seizing this opportunity by leveraging blockchain and related technologies to secure and streamline clinical operations, making them tamper-resistant and more efficient.
Verial eTMF: A Proven Blockchain Solution
Over the past three years, Triall has developed and commercialized its first product, Verial eTMF, which enables researchers to anchor research data on the blockchain, thereby ensuring the integrity of clinical trial data. The product is already being used and onboarded by six clinical trials, including projects related to Irritable Bowel Syndrome (IBS), autoimmune diseases, and a COVID-19 vaccine. Verial eTMF is the first of many blockchain-enabled applications that will be integrated into a single digital platform: the Triall ecosystem. This approach aims to create a seamless environment where all stakeholders can securely share and verify data.
TRL Token: Fueling the Micro-Economy
The TRL token serves as the primary means of payment for software solutions within the Triall ecosystem. Beyond payments, it enables peer-to-peer compensation, community engagement, governance, and loyalty programs such as memberships and staking. The tokenomic model is designed to create a self-sustaining micro-economy that rewards participants and aligns incentives across the clinical trial supply chain.
Strategic Partnerships and Global Reach
Triall has built a strong network across the EU and US clinical trial spaces, supported by global partners and advisors, including industry experts and key opinion leaders. The company has partnered with several prominent crypto firms, including LTO Network, Zokyo, Faculty Group, Ferrum Network, as well as launchpads TrustPad and Prostarter. These collaborations enhance Triall's technological foundation and market access.
CEO Vision for the Future
“This is the right time for disruptive innovations to demonstrate their added value in clinical operations and make their way to industry-wide adoption,” said Hadil Es-Sbai, CEO of Triall. “Our first product is currently being onboarded in a growing number of clinical trials. We can’t wait for the day when Triall will be recognized as the go-to ecosystem for a range of essential products that enable faster, smarter, and more-efficient clinical trials.” Triall aims to bring Web 3.0 to medical research by creating a digital ecosystem of blockchain-integrated software solutions that secure and streamline the development of new vaccines and therapeutics, solving real industry pain points.